The literature on risk factors for cardiometabolic diseases showed that lutein might be beneficial for atherosclerosis and inflammatory markers , but there were inconsistent associations with blood pressure , adiposity , insulin resistance , and blood lipids .
CONCLUSIONS Our findings suggest that higher dietary intake and higher blood concentrations of lutein are generally associated with better cardiometabolic health .
BACKGROUND The antioxidant lutein is suggested as being beneficial to cardiometabolic health because of its protective effect against oxidative stress , but evidence has not systematic ally been evaluated .
OBJECTIVE We aim ed to evaluate systematic ally the effects of lutein ( intake or concentrations ) on cardiometabolic outcomes in different life stages .
Assessment of carotenoid status and the relation to glycaemic control in type I diabetics: a follow-up study
Objective : To assess the carotenoid status in young type I diabetic patients and its relationship to the glycaemic control of the disease . Design : A follow-up study . Setting : Hospital Universitario Puerta de Hierro , Health Area VI of Madrid (Spain).Subjects : Forty-seven type I diabetic patients , followed for 2.5 years . Interventions : Coinciding with physical examination and laboratory tests , serum levels of carotenoids were analysed by HPLC , and dietary intake of carotenoids was evaluated by a semiquantitative food frequency question naire and 3-day prospect i ve dietary records . Results : In type I diabetic patients , average intake , serum levels and correlations between diet and serum levels of carotenoids were comparable to those in reference non-diabetic groups . Between-subjects seasonal variations were observed for β-cryptoxanthin intake and serum levels ( higher in winter ) and serum lycopene ( higher in summer ) . Significant within-subjects seasonal changes were shown for dietary and serum β-cryptoxanthin and serum β-carotene . Serum carotenoids were unrelated to glycaemic control markers . Subjects with clinical ly acceptable glycaemic control showed lower lycopene intake than those with unacceptable control . Intake of carotenoids did not explain variance in insulin dose , fasting glycaemia , fructosamine or HbA1c . With the exception of lycopene , serum carotenoids were predicted by dietary intake , but in no case by fasting glycaemia , HbA1c or fructosamine . Conclusion : In type I diabetic patients , serum carotenoid concentrations and their variance are determined by dietary intake patterns , and are unrelated to the glycaemic control of the disease , as assessed by biochemical markers
The literature on risk factors for cardiometabolic diseases showed that lutein might be beneficial for atherosclerosis and inflammatory markers , but there were inconsistent associations with blood pressure , adiposity , insulin resistance , and blood lipids .
CONCLUSIONS Our findings suggest that higher dietary intake and higher blood concentrations of lutein are generally associated with better cardiometabolic health .
BACKGROUND The antioxidant lutein is suggested as being beneficial to cardiometabolic health because of its protective effect against oxidative stress , but evidence has not systematic ally been evaluated .
OBJECTIVE We aim ed to evaluate systematic ally the effects of lutein ( intake or concentrations ) on cardiometabolic outcomes in different life stages .